Table 3.
Multivariable analyses for ORR, PFS and OS in pembrolizumab cohort considering GRImΔ as independent variable.
| Test Variables | ORR OR (95% CI) | p-Value | PFS HR (95% CI) | p-Value | OS HR (95% CI) | p-Value |
|---|---|---|---|---|---|---|
| GRImΔ positive-stable (ref.)/negative | 0.74 (0.50–1.08) | 0.12 | 6.98 (2.94–16.61) | <0.01 a | 3.28 (1.39–7.74) | <0.01 a |
| Never smokers (ref.)/ Current-former smokers |
1.13 (0.67–1.89) | 0.64 | 0.83 (0.24–2.90) | 0.78 | 0.34 (0.09–1.21) | 0.10 |
| ECOG PS 0–1 (ref.)/≥2 | 0.87 (0.58–1.29) | 0.50 | 0.95 (0.38–2.38) | 0.92 | 0.81 (0.27–2.43) | 0.71 |
| Non adenocarcinoma (ref.)/ Adenocarcinoma |
0.79 (0.54–1.15) | 0.22 | – | – | – | – |
| Metastatic sites ≤2/>2 | – | – | 1.28 (0.59–2.77) | 0.52 | 1.15 (0.54–2.47) | 0.70 |
| PD-L1 percentage <78/≥78 | 1.21 (0.91–1.60) | 0.17 | – | – | – | – |
| Liver metastases No. (ref.)/Yes | – | – | 2.14 (0.85–5.40) | 0.10 | – | – |
| Bone metastases No. (ref.)/Yes | 0.85 (0.62–1.15) | 0.30 | – | – | – | – |
CI, confidence interval; ORR, objective response rate; OR, odds ratio; PFS, progression-free survival; HR, hazard ratio; OS, overall survival; GRImΔ, GRIm-Score variation between the two timepoints; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death-ligand 1; No., number. a Statistically significant (p < 0.05).